Oncolytics Biotech Files October 2025 6-K Report
Ticker: ONCY · Form: 6-K · Filed: Oct 10, 2025 · CIK: 1129928
Sentiment: neutral
Topics: foreign-private-issuer, regulatory-filing, pharmaceutical
Related Tickers: ONCO
TL;DR
ONCOLYTICS BIOTECH (ONCO) filed its October 6-K, standard foreign private issuer update.
AI Summary
Oncolytics Biotech Inc. filed a Form 6-K on October 10, 2025, reporting as a foreign private issuer. The company, based in Calgary, Alberta, Canada, is involved in the pharmaceutical preparations industry (SIC code 2834). This filing is for the month of October 2025 and is submitted under the 1934 Securities Exchange Act.
Why It Matters
This filing provides routine updates for investors and regulatory bodies regarding Oncolytics Biotech Inc.'s status as a foreign private issuer.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain specific financial or operational news that would indicate a change in risk.
Key Players & Entities
- ONCOLYTICS BIOTECH INC (company) — Filer of the 6-K report
- October 10, 2025 (date) — Filing date of the 6-K
- Calgary, Alberta, Canada (location) — Company's principal executive offices
- 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, used to provide information that the registrant makes or is required to make public in its home country, files or is required to file with a stock exchange, or distributes or is required to distribute to its security holders.
What is the SIC code for Oncolytics Biotech Inc.?
The Standard Industrial Classification (SIC) code for Oncolytics Biotech Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Where are Oncolytics Biotech Inc.'s principal executive offices located?
Oncolytics Biotech Inc.'s principal executive offices are located at Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5.
What is the filing date of this specific Form 6-K?
This specific Form 6-K was filed as of October 10, 2025.
Under which act is this Form 6-K filed?
This Form 6-K is filed under the Securities Exchange Act of 1934.
Filing Stats: 375 words · 2 min read · ~1 pages · Grade level 15.2 · Accepted 2025-10-10 17:28:47
Filing Documents
- tm2528273d1_6k.htm (6-K) — 11KB
- tm2528273d1_ex99-1.htm (EX-99.1) — 40KB
- tm2528273d1_ex99-1img001.jpg (GRAPHIC) — 82KB
- tm2528273d1_ex99-1img002.jpg (GRAPHIC) — 233KB
- tm2528273d1_ex99-1img003.jpg (GRAPHIC) — 144KB
- tm2528273d1_ex99-1img004.jpg (GRAPHIC) — 207KB
- tm2528273d1_ex99-1img005.jpg (GRAPHIC) — 131KB
- tm2528273d1_ex99-1img006.jpg (GRAPHIC) — 149KB
- tm2528273d1_ex99-1img007.jpg (GRAPHIC) — 179KB
- tm2528273d1_ex99-1img008.jpg (GRAPHIC) — 61KB
- tm2528273d1_ex99-1img009.jpg (GRAPHIC) — 179KB
- tm2528273d1_ex99-1img010.jpg (GRAPHIC) — 144KB
- tm2528273d1_ex99-1img011.jpg (GRAPHIC) — 172KB
- tm2528273d1_ex99-1img012.jpg (GRAPHIC) — 134KB
- tm2528273d1_ex99-1img013.jpg (GRAPHIC) — 161KB
- tm2528273d1_ex99-1img014.jpg (GRAPHIC) — 165KB
- tm2528273d1_ex99-1img015.jpg (GRAPHIC) — 183KB
- tm2528273d1_ex99-1img016.jpg (GRAPHIC) — 163KB
- tm2528273d1_ex99-1img017.jpg (GRAPHIC) — 107KB
- tm2528273d1_ex99-1img018.jpg (GRAPHIC) — 68KB
- tm2528273d1_ex99-1img019.jpg (GRAPHIC) — 176KB
- tm2528273d1_ex99-1img020.jpg (GRAPHIC) — 131KB
- tm2528273d1_ex99-1img021.jpg (GRAPHIC) — 167KB
- 0001104659-25-098796.txt ( ) — 4361KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) Date: October 10, 2025 By: /s/ Kirk Look Kirk Look Chief Financial Officer